Progress in Research and Application of HIV-1 TAT-Derived Cell-Penetrating Peptide.

Le Zou, Qilin Peng, Ping Wang, Boting Zhou

Journal: The Journal of membrane biology 2017;250(2):115-122

PMID: 27933338

Abstract

Human immunodeficiency virus type I (HIV-1) transactivator of transcription (TAT) is encoded by HIV-1. It is a peptide rich in basic amino acids and belongs to the protein transduction domain family. It has been found that HIV-1 TAT and its core peptide segment TAT play an important role in promoting the cellular uptake of coupled bioactive macromolecules, such as peptides, proteins, oligonucleotides, and drug molecules. HIV-1 TAT can also significantly increase the soluble expression of extrinsic proteins. However, the mechanism behind the cellular uptake of HIV-1 TAT-derived cell-penetrating peptide remains unclear. This review focuses on the research into HIV-1 TAT-derived cell-penetrating peptide over the last years. We briefly discuss TAT's structural features, functions and applications, the mechanism of its cellular internalization, current challenges, and their possible solutions. At the end of this review, we provide a summary and predict the future research directions and potential applications of HIV-1 TAT when it is used as a cell-penetrating peptide.

Address: Department of Pharmacy, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Changsha, 410008, Hunan Province, China.; Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China.; Department of Pharmacy, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Changsha, 410008, Hunan Province, China. [email protected].; Institute of Hospital Pharmacy, Central South University, Changsha, 410008, China. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.